Anavex Life Sciences (AVXL) vs Cellectis S.A. (CLLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cellectis S.A. (CLLS) has outperformed Anavex Life Sciences (AVXL) over the past year, losing 70.9% versus a loss of 84.4%. Over five years, CLLS leads with a -88.5% price change compared with -91.2% for AVXL. Anavex Life Sciences is the larger company by market cap ($134.9 million vs $126.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVXL | CLLS |
|---|---|---|
| Share price | $1.46 | $1.26 |
| Market cap | $134.87M | $126.42M |
| 1-day change | -5.52% | +0.40% |
| YTD return | -56.74% | -74.17% |
| 1-year return | -84.37% | -70.93% |
| 5-year return | -91.21% | -88.46% |
| EPS (TTM) | $-0.14 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.53 | $5.48 |
| 52-week low | $1.44 | $1.22 |
| Distance from 52-week high | -84.72% | -77.10% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +324.70% |
| Average volume | 979.69K | 80.14K |
| Shares outstanding | 92.70M | 72.73M |
| Employees | 34 | 224 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLLS has outperformed AVXL by 13.4 percentage points over the past year.
About Anavex Life Sciences
AVXL stock →Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
AVXL vs CLLS FAQ
Which is bigger, Anavex Life Sciences or Cellectis S.A.?
Anavex Life Sciences (AVXL) is larger, with a market capitalization of $134.87M compared with $126.42M for Cellectis S.A. (CLLS).
Which stock has performed better over the past year, AVXL or CLLS?
CLLS returned -70.93% over the past 12 months, compared with -84.37% for AVXL (price return, excluding dividends). Past performance does not predict future results.
Are Anavex Life Sciences and Cellectis S.A. in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Anavex Life Sciences and Biotechnology: Pharmaceutical Preparations for Cellectis S.A..